Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research

Q&A with FDA Podcast: FDA takes steps to decrease barriers for overdose reversal agents with Dr. Marta Sokolowska

Enroll
Step Status
Educational Content ✘
Posttest ✘
Evaluation ✘
Starts On: Tue, 1/16/24: 12:00 AM EST
Ends On: Fri, 1/15/27: 12:00 AM EST
Type: Enduring Material
Credits: 0.5
Description: This enduring material takes a deeper dive into one of the four key priorities in the FDA's Overdose Prevention Framework: encouraging harm reduction. It focuses on the Agency's vision as it relates to encouraging harm reduction, including expanding availability and access to lifesaving overdose reversal products. The discussion focuses on the impacts of the recent approvals of nonprescription naloxone nasal spray as well as prescription nalmefene nasal spray, another medication for opioid overdose.
Objectives:
  • Explain the implications of over-the-counter (OTC) approval of naloxone nasal spray and what this means for harm reduction in opioid users
  • Discuss the transition period regarding nonprescription naloxone nasal spray and when consumers can anticipate this product on OTC shelves
  • Outline important information regarding the recent approval of prescription nalmefene nasal spray
Additional Information: Review the Activity Announcement for additional details: Announcement Form